CASI Pharmaceuticals, Inc. (CASI)

Market Cap	20.14M
Revenue (ttm)	31.37M
Net Income (ttm)	-40.48M
Shares Out	15.49M
EPS (ttm)	-2.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,568
Open	1.380
Previous Close	1.330
Day's Range	1.300 - 1.390
52-Week Range	1.091 - 7.670
Beta	0.52
Analysts	Strong Buy
Price Target	4.00 (+207.69%)
Earnings Date	Aug 15, 2025

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company’s hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-FcγRIIB antib...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 1996
• Employees: 233
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI
• Website: https://www.casipharmaceuticals.com

Financial Performance

In 2024, CASI Pharmaceuticals's revenue was $28.54 million, a decrease of -15.77% compared to the previous year's $33.88 million. Losses were -$39.26 million, 45.6% more than in 2023.

Analyst Summary

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(207.69% upside)

Analyst Consensus: Strong Buy